Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies-Reference-Cited by-同舟云学术

Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies

Published:2020-10-14 Issue:11 Volume:72 Page:e887-e889
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

McCaw Zachary R¹^ORCID,Tian Lu²,Kim Dae Hyun³,Localio A Russell⁴,Wei Lee-Jen⁵^ORCID

Affiliation:

1. Google, Mountain View, California, USA

2. Department of Biomedical Data Science, Stanford University, Stanford, California, USA

3. Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA

4. Division of Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

5. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA

Abstract

Abstract For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1563/34144691/ciaa1563.pdf

Reference7 articles.

1. Dexamethasone in hospitalized patients with Covid-19—preliminary report [manuscript published online ahead of print 17 July 2020];RECOVERY Collaborative Group;New Engl J Med,2020

2. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves;Guyot;BMC Med Res Methodol,2012

3. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis;Uno;J Clin Oncol,2014

4. Restricted mean survival time as a measure to interpret clinical trial results;Kim;JAMA Cardiol,2017

5. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio;Pak;JAMA Oncol,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A survival analysis of COVID-19 cases for Bah cluster in Malaysia;The 5th Innovation and Analytics Conference & Exhibition (IACE 2021);2022

2. Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov;Trials;2021-11-08

3. Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials;Frontiers in Public Health;2021-09-28

4. A Systematic Review and Network Meta-Analysis for COVID-19 Treatments;2020-12-22